ArticleCureus2025
Assessing the Knowledge of Diabetic Patients About Glucagon Use in Hypoglycemia: A Cross-Sectional Study in Riyadh, Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim Glucagon is a critical intervention for severe hypoglycemia in diabetic patients. However, knowledge about its use remains insufficient among patients. This study aimed to assess the knowledge level related to glucagon in diabetic patients in Riyadh, Saudi Arabia. Methods This cross-sectional survey was conducted among diabetic patients aged 18 years and above in Riyadh, Saudi Arabia. Participants were recruited via social media, diabetes mellitus support groups, and healthcare facilities. The questionnaire collected demographic data, diabetes-related information, and knowledge regarding glucagon use. Results The study included 643 respondents, with a majority from the 24 to 34-year age group. Males constituted 60.3% (n=388) of the participants' population. The majority of participants (70.6%, n=454) had type 2 diabetes mellitus (T2DM), whereas 29.4% (n=189) had type 1 diabetes mellitus (T1DM). The majority of respondents stated that they had experienced hypoglycemia (58.3%, n=375), with 43.2% (n=278) experiencing severe hypoglycemia. A total of 69.2% (n=445) of participants were not aware of glucagon injection. Out of those who were aware, 34.3% (n=68) did not have glucagon injection at home, and 17.7% (n=35) were unaware of how to use it. Knowledge of glucagon was higher among younger individuals, those with higher education, and employed participants (p<0.05). T1DM patients showed significantly greater knowledge of glucagon compared to those with T2DM (p<0.05). Those with diabetes for less than five years were more likely to know about the use of glucagon (p<0.05). Conclusions There is a significant gap in glucagon knowledge and availability among diabetic patients in Riyadh. Therefore, diabetic patients should be educated about glucagon, especially those with a longer duration of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.